Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565931 | 1.00 | MAPT (0.62) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL3613205 | 0.95 | MAPT (0.57) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL214913 | 0.89 | MAPT (0.60) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL470199 | 0.89 | MAPT (0.56) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL29803690 | 0.89 | MAPT (0.60) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL31130013 | 0.89 | MAPT (0.56) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL31130014 | 0.89 | MAPT (0.56) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL4722818 | 0.89 | MAPT (0.60) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL7242118 | 0.88 | MAPT (0.56) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL20352117 | 0.88 | MAPT (0.55) | MAPTALDH1A1LMNAPDK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3200589-B1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-08 | — | — | US | disclosed |
| CN-118344358-A | HPK1 inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-07-16 | — | — | CN | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2014121062-A1 | SELECTIVE HDAC3 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014121062-A1 | SELECTIVE HDAC3 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-6069143-A | Fibrinogen receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | MAPT 2138/4885ALDH1A1 4295/4885LMNA 4821/4885 |
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS1, LGALS3BP | MAPT 3151/4885ALDH1A1 2713/4885LMNA 1394/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | MAPT 2761/4885ALDH1A1 2009/4885LMNA 3835/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | MAPT 3260/4885ALDH1A1 2343/4885LMNA 1961/4885 |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | MAPT 1051/4885ALDH1A1 2423/4885LMNA 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.